[Implantable Intravitreal Corticosteroids in Chronic Noninfectious Uveitis]

Overview

Journal Ophthalmologie

Specialty Ophthalmology

Date 2024 Aug 15

PMID 39145783

Authors

L J Kessler

M Albrecht

T Naujokaitis

G Auffarth

Ramin Khoramnia

Affiliations

Soon will be listed here.

Abstract

Background: Uveitis leads to blindness in 10-15% of all cases in industrialized nations. The prevalence varies depending on the literature, ranging from 9 to 730 cases per 100,000 inhabitants. Local and systemic steroid applications, along with treatment involving immunomodulators, are the primary treatment options. In cases of chronic and refractory uveitis, especially with the manifestation of uveitic macular edema, intravitreal corticosteroids can contribute to reduce or completely replace systemic immunomodulatory therapy with disease-modifying antirheumatic drugs (DMARDs), biologics or corticosteroids.

Objective: This review article presents the currently available intravitreal corticosteroid implants used in the treatment of noninfectious uveitis. The indications, effectiveness, and side effect profiles are discussed within the context of the current literature. A total of 6 randomized controlled studies about FAc and DEX implants with more than 100 patients were included in this review. One subgroup analysis from a multicentric randomized study with 315 patients has been included as well. The outcome is discussed in this article.

Conclusion: The efficacy and safety profile of intravitreal corticosteroids in uveitic macular edema have been evaluated in several studies in recent years. In some studies, they have been compared to systemic treatment options. With long-acting corticosteroid implants the number of relapses can be reduced and the time interval between relapses can be prolonged. Short-acting corticosteroid implants represent a treatment option during acute uveitic activity. The adverse effects of corticosteroids can be well-controlled in most cases. In phakic and/or young patients, however, adverse effects (such as cataract development) should be discussed in depth before treatment initiation as most corticosteroids are applied as long-term treatment.

References

Acharya N, Vitale A, Sugar E, Holbrook J, Burke A, Thorne J . Intravitreal Therapy for Uveitic Macular Edema-Ranibizumab versus Methotrexate versus the Dexamethasone Implant: The MERIT Trial Results. Ophthalmology. 2023; 130(9):914-923. PMC: 10524707. DOI: 10.1016/j.ophtha.2023.04.011. View

Augustin A, Bopp S, Fechner M, Holz F, Sandner D, Winkgen A . Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN (0.19 mg fluocinolone acetonide implant). Eur J Ophthalmol. 2019; 30(2):382-391. PMC: 7079293. DOI: 10.1177/1120672119834474. View

Battista M, Starace V, Cicinelli M, Capone L, Marchese A, Modorati G . Efficacy of 0.19 mg Fluocinolone Acetonide Implant in Non-infectious Posterior Uveitis Evaluated as Area Under the Curve. Ophthalmol Ther. 2021; 11(1):215-224. PMC: 8770757. DOI: 10.1007/s40123-021-00426-2. View

Baudin F, Benzenine E, Mariet A, Bron A, Daien V, Korobelnik J . Association of Acute Endophthalmitis With Intravitreal Injections of Corticosteroids or Anti-Vascular Growth Factor Agents in a Nationwide Study in France. JAMA Ophthalmol. 2018; 136(12):1352-1358. PMC: 6583044. DOI: 10.1001/jamaophthalmol.2018.3939. View

Bodaghi B, Nguyen Q, Jaffe G, Khoramnia R, Pavesio C . Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye - evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN). J Ophthalmic Inflamm Infect. 2020; 10(1):32. PMC: 7701203. DOI: 10.1186/s12348-020-00225-z. View

Buhl L, Thurau S, Kern C . Fluocinolone acetonide 0.19-mg implant for the treatment of noninfectious uveitis with involvement of the posterior segment: a real-world study. Graefes Arch Clin Exp Ophthalmol. 2022; 261(4):1101-1108. PMC: 10050064. DOI: 10.1007/s00417-022-05893-2. View

Callanan D, Jaffe G, Martin D, Pearson P, Comstock T . Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol. 2008; 126(9):1191-201. DOI: 10.1001/archopht.126.9.1191. View

Campochiaro P, Nguyen Q, Hafiz G, Bloom S, Brown D, Busquets M . Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2012; 120(3):583-587. DOI: 10.1016/j.ophtha.2012.09.014. View

Chang-Lin J, Burke J, Peng Q, Lin T, Orilla W, Ghosn C . Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci. 2011; 52(7):4605-9. DOI: 10.1167/iovs.10-6387. View

10.

Haghjou N, Soheilian M, Abdekhodaie M . Sustained release intraocular drug delivery devices for treatment of uveitis. J Ophthalmic Vis Res. 2012; 6(4):317-29. PMC: 3306122. View

11.

Hikal M, Celik N, Auffarth G, Kessler L, Mayer C, Khoramnia R . Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis. J Clin Med. 2021; 10(17). PMC: 8432003. DOI: 10.3390/jcm10173966. View

12.

Jaffe G, Guo H, Dunn J, Ashton P . Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000; 107(11):2024-33. DOI: 10.1016/s0161-6420(00)00466-8. View

13.

Jaffe G, Foster C, Pavesio C, Paggiarino D, Riedel G . Effect of an Injectable Fluocinolone Acetonide Insert on Recurrence Rates in Chronic Noninfectious Uveitis Affecting the Posterior Segment: Twelve-Month Results. Ophthalmology. 2018; 126(4):601-610. DOI: 10.1016/j.ophtha.2018.10.033. View

14.

Kempen J, Altaweel M, Holbrook J, Jabs D, Louis T, Sugar E . Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011; 118(10):1916-26. PMC: 3191365. DOI: 10.1016/j.ophtha.2011.07.027. View

15.

Kessler L, Auffarth G, Khoramnia R . Functional and Morphological Responses to Fluocinolone Acetonide 0.19 mg in Noninfectious Uveitic Macular Edema Evaluated as the Area-Under-the-Curve. J Ocul Pharmacol Ther. 2023; 39(7):449-455. PMC: 10516239. DOI: 10.1089/jop.2023.0027. View

16.

Kessler L, Labuz G, Auffarth G, Khoramnia R . Biomarkers to Predict the Success of Treatment with the Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Uveitic Macular Edema. Pharmaceutics. 2022; 14(4). PMC: 9028038. DOI: 10.3390/pharmaceutics14040688. View

17.

Khoramnia R, Peto T, Koch F, Taylor S, de Sousa J, Hill L . Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study. Br J Ophthalmol. 2022; 107(10):1502-1508. PMC: 10579189. DOI: 10.1136/bjo-2022-321415. View

18.

Kwak H, DAmico D . Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol. 1992; 110(2):259-66. DOI: 10.1001/archopht.1992.01080140115038. View

19.

Lowder C, Belfort Jr R, Lightman S, Foster C, Robinson M, Schiffman R . Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011; 129(5):545-53. DOI: 10.1001/archophthalmol.2010.339. View

20.

Pavesio C, Zierhut M, Bairi K, Comstock T, Usner D . Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology. 2010; 117(3):567-75, 575.e1. DOI: 10.1016/j.ophtha.2009.11.027. View